The Activity of Crizotinib in Chemo-Refractory MET -Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcS é-Crizotinib Program

ConclusionsLarge-scale screening forMET-amplified esogastric adenocarcinomas is feasible.MET amplification was observed in 5.5% of gastric and 12.8% of esophageal adenocarcinomas. Crizotinib shows encouraging results in selected patients. Thus, c-MET inhibition forMET-amplified tumors deserves further evaluation.Trial Registration NumberNCT02034981.Date of Registration14 January 2014.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research